Pharmacists Play Key Role in Combating C. diff Infections

Updated June 18, 2025

Patients entering ⁣health care facilities expect to recieve⁢ optimal care and improve their health. However, those treated with antibiotics or staying in ⁢hospitals or nursing homes ⁤face a higher ⁢risk of contracting⁣ Clostridioides difficile (C. diff), a bacterium causing⁤ severe gastrointestinal issues. ‍The ⁤centers for Disease Control and Prevention (CDC) estimates that C. diff infections affect nearly half a ⁤million people in the U.S. each year.

C. diff typically leads to diarrhea and colitis. While anyone can contract it, antibiotic use disrupts the gut’s bacterial balance, allowing C. diff to ‍proliferate. Infected⁢ individuals release spores ⁢that spread through skin and⁢ surfaces, facilitating transmission in health care settings.

Treatment options are limited. Initially, ⁣doctors may discontinue the antibiotic causing the infection. Historically, metronidazole ⁤was used for mild ⁢to moderate cases,⁢ but ⁣its effectiveness has decreased⁣ due to resistant strains. Current treatments include vancomycin or fidaxomicin. For ⁣severe infections, metronidazole might potentially be⁢ used intravenously or with vancomycin. Despite treatment, about 25% of patients experience repeat infections.

Recurrent⁣ C. diff infections can occur if the initial infection persists or a new one develops. Patients over‍ 65, those on antibiotics for other conditions, or those with severe medical issues are at higher risk. While⁣ antibiotic therapy can be ⁤used again, its effectiveness diminishes with each recurrence. Given the recurrence risk ⁣and ease of spread, C.diff remains a meaningful public health concern, especially among older adults and⁤ children.

Pharmacists play a crucial role in monitoring patients and advocating for effective C. diff treatment. Organizations like the Peggy Lillis Foundation provide support for patients and caregivers. Dr. Stacy A. Khan of Boston Children’s hospital ‍emphasized the importance of pharmacists staying updated on C. diff literature and collaborating with multidisciplinary teams to improve patient outcomes.

“What you learned‍ when you⁣ were ⁣getting your master’s degree in pharmacy or your bachelor’s may⁣ not hold true anymore,” ⁤Khan said. “Certainly, when I ⁣did training, ⁤metronidazole was the first-line treatment⁣ for C. Tough. We⁣ now know that, in most cases, there are other treatments that are much more effective and have a ⁤higher chance of achieving a cure and don’t have the same kind of effects that are so unpleasant.”

Pharmacists can apply lessons learned⁢ from the COVID-19 pandemic to prevent C. diff infections. Antimicrobial stewardship programs help patients optimize antibiotic use, ⁢reducing C. diff infections. Educating patients on lifestyle changes and symptom management is also ⁢key.

Pharmacists ‍can also recommend novel approaches like fecal microbiota transplant, transferring ⁤healthy donor stool to affected ⁤patients to ⁣prevent recurrent infections. The Peggy Lillis ⁤Foundation advocates for funding and research into such treatments.

“Patient education and support really make a difference,” said ⁣Dr. Bruce E. Hirsch, an infectious disease physician at Northwell Health. “When your patient understands what he or she is going ⁢through, it is empowering the patient, and I do⁤ think that patient knowledge is such an important part of adherence and understanding how to take medications appropriately.”

what’s next

Continued research and advocacy are essential to ‍combat C. ⁣diff infections. Further studies into novel treatments and increased awareness among ⁣health care providers and the public are crucial steps in reducing the impact of this persistent public health threat.